Table 2 |
|||
|
Fasting PCSK9 and lipid levels pre- and post-atorvastatin treatment |
|||
| Baseline |
Treatment |
% Change |
|
|
|
|||
| PCSK9 (μg/mL) |
5.88 ± 1.70 |
6.32 ± 2.29* |
7.40 ± 25.3 |
| Total cholesterol |
5.82 ± 0.76 |
4.37 ± 0.62*** |
-25.0 ± 9.06 |
| Triglycerides |
1.50 ± 0.56 |
1.26 ± 0.58** |
-16.2 ± 28.0 |
| HDL cholesterol |
1.32 ± 0.26 |
1.43 ± 0.30*** |
8.03 ± 13.2 |
| LDL cholesterol |
3.82 ± 0.67 |
2.37 ± 0.53*** |
-38.0 ± 10.3 |
| TC/HDLC Ratio |
4.53 ± 0.89 |
3.17 ± 0.63*** |
-30.1 ± 9.79 |
|
Significance comparing baseline and treatment by Wilcoxon's signed rank test (n = 40). Values expressed as μmol/L except where indicated. *p < 0.05, **p < 0.001, ***p < 0.0001 | |||
Mayne et al. Lipids in Health and Disease 2008 7:22 doi:10.1186/1476-511X-7-22 |
|||
